MA45047A - Procédés d'utilisation d'inhibiteurs de fasn - Google Patents

Procédés d'utilisation d'inhibiteurs de fasn

Info

Publication number
MA45047A
MA45047A MA045047A MA45047A MA45047A MA 45047 A MA45047 A MA 45047A MA 045047 A MA045047 A MA 045047A MA 45047 A MA45047 A MA 45047A MA 45047 A MA45047 A MA 45047A
Authority
MA
Morocco
Prior art keywords
methods
fasn inhibitors
fasn
inhibitors
Prior art date
Application number
MA045047A
Other languages
English (en)
Inventor
Sailaja Battula
Wei Lu
David S Millan
Stephane Soroosh Radfar
Seng-Lai Tan
Original Assignee
Forma Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forma Therapeutics Inc filed Critical Forma Therapeutics Inc
Publication of MA45047A publication Critical patent/MA45047A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA045047A 2016-04-25 2017-04-25 Procédés d'utilisation d'inhibiteurs de fasn MA45047A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662327167P 2016-04-25 2016-04-25

Publications (1)

Publication Number Publication Date
MA45047A true MA45047A (fr) 2019-03-27

Family

ID=60157111

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045047A MA45047A (fr) 2016-04-25 2017-04-25 Procédés d'utilisation d'inhibiteurs de fasn

Country Status (9)

Country Link
US (2) US20170312273A1 (fr)
EP (1) EP3458448B1 (fr)
DK (1) DK3458448T3 (fr)
ES (1) ES2886935T3 (fr)
MA (1) MA45047A (fr)
PL (1) PL3458448T3 (fr)
PT (1) PT3458448T (fr)
TW (1) TW201737943A (fr)
WO (1) WO2017189613A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3587406B1 (fr) 2013-03-13 2021-01-27 Forma Therapeutics, Inc. Dérivés de 2-hydroxy-1-{4-[(4-phénylphényl)carbonyl]pipérazin-1-yl}éthan-1-one et composés similaires en tant qu'inhibiteurs de la synthase d'acide gras (fasn) pour le traitement du cancer
MX393780B (es) 2017-01-17 2025-03-24 Heparegenix Gmbh Inhibidores de proteina cinasa para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocitos
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
WO2020092376A1 (fr) * 2018-10-29 2020-05-07 Forma Therapeutics, Inc. Traitement de la stéatohépatite non alcoolique (shna)
CN113382633A (zh) 2018-10-29 2021-09-10 福马治疗股份有限公司 (4-(2-氟-4-(1-甲基-1H-苯并[d]咪唑-5-基)苯甲酰基)哌嗪-1-基)(1-羟基环丙基)甲酮的固体形式
CN113265468B (zh) * 2021-07-21 2021-10-12 北京大学第三医院（北京大学第三临床医学院） 一种与宫颈癌诊断、治疗和预后相关的miRNA
WO2023086483A1 (fr) * 2021-11-11 2023-05-19 Sagimet Biosciences Inc. Procédés de prédiction de la réponse au traitement dans une stéatose hépatique non alcoolique
WO2023093700A1 (fr) * 2021-11-29 2023-06-01 中国海洋大学 Dérivé d'imidazothiazole, son procédé de préparation et son utilisation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
KR20100014652A (ko) * 2007-02-27 2010-02-10 파스겐 다이아그노스틱스, 엘엘씨 간 질환에서의 지방산 합성효소
EP3587406B1 (fr) 2013-03-13 2021-01-27 Forma Therapeutics, Inc. Dérivés de 2-hydroxy-1-{4-[(4-phénylphényl)carbonyl]pipérazin-1-yl}éthan-1-one et composés similaires en tant qu'inhibiteurs de la synthase d'acide gras (fasn) pour le traitement du cancer
CN105008329B (zh) 2013-03-21 2018-01-05 默克专利股份公司 作为fasn抑制剂的哌嗪衍生物
US9562035B2 (en) * 2013-12-03 2017-02-07 Janssen Pharmaceutica Nv Benzamide derivative useful as FASN inhibitors for the treatment of cancer
CA2934257C (fr) * 2013-12-17 2022-06-07 Janssen Pharmaceutica Nv Derive d'imidazoline-5-one utile en tant qu'inhibiteur de fas pour le traitement du cancer

Also Published As

Publication number Publication date
WO2017189613A1 (fr) 2017-11-02
EP3458448A1 (fr) 2019-03-27
TW201737943A (zh) 2017-11-01
US20170312273A1 (en) 2017-11-02
US20190374536A1 (en) 2019-12-12
PL3458448T3 (pl) 2021-12-06
PT3458448T (pt) 2021-09-10
EP3458448B1 (fr) 2021-06-23
DK3458448T3 (da) 2021-08-23
ES2886935T3 (es) 2021-12-21
EP3458448A4 (fr) 2019-04-17

Similar Documents

Publication Publication Date Title
EP3600318A4 (fr) Procédés d'utilisation d'inhibiteurs d'ehmt2
MA54543A (fr) Inhibiteurs de kif18a
MA54550A (fr) Inhibiteurs de kif18a
DK3612525T3 (da) Pd-1-/pd-l1-inhibitorer
EP3843714A4 (fr) Inhibiteurs de cd73
MA51616A (fr) Inhibiteurs d'adn-pk
EP3380101A4 (fr) Composés inhibiteurs d'eif4-a et procédés associés
MA52413A (fr) Inhibiteurs de cd73
EP3801503A4 (fr) Inhibiteurs de sarm1
MA55748A (fr) Procédés de détection d'aav
MA44392A (fr) Procédés d'utilisation d'activateurs de la pyruvate kinase
EP3436581A4 (fr) Procédés d'amplification de transcriptome entier
MA43365A (fr) Anticorps anti-dr5 et procédés d'utilisation de ceux-ci
MA45047A (fr) Procédés d'utilisation d'inhibiteurs de fasn
EP3347008A4 (fr) Inhibiteurs de bêta-lactamases
DK3442972T3 (da) Bromdomænehæmmere
EP3430170A4 (fr) Procédés pour la caractérisation de génomes
DK3575022T3 (da) Værktøjssystem
EP3787635A4 (fr) Inhibiteurs de cd73
EP3688132A4 (fr) Solutions de décapage et procédés d'utilisation de solutions de décapage
MA55193A (fr) Procédés de préparation d'un inhibiteur de pi3k
EP3621660A4 (fr) Compositions et procédés d'utilisation de capsides arc
MA52813A (fr) Inhibiteurs de sarm1
CL2016002638A1 (es) Nuevos inhibidores de la nitrificación
MA41296A (fr) Procédés de transdifférenciation et procédés d'utilisation de ceux-ci